ReviewJournal of bone oncology2026
Tenosynovial giant cell tumor of the hip: a systematic review and institutional case series with Meta-analysis of recurrence and patient-reported outcomes.
Review in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tenosynovial giant cell tumors (TGCT) are rare, locally aggressive neoplasms of the synovium, most frequently affecting the knee and less commonly the hip. Due to its deep anatomy and weight-bearing function, hip TGCT may follow a distinct clinical course. This study evaluates clinical presentation, treatment outcomes, recurrence patterns, and patient-reported outcomes in hip TGCT. Methods: A systematic literature search in PubMed, Embase, and Cochrane Library (January 2000-May 2025) identified studies including ≥5 patients with hip TGCT reporting recurrence, complications, functional outcomes or patient-reported outcomes. A random-effects meta-analysis assessed recurrence risk across treatment modalities. Additionally, 23 patients of two retrospective institutional cohorts were analyzed, including PROMIS-CAT assessment. Results: Seventeen studies comprising 269 patients were included. The mean age was 32 years and 58% were female. At diagnosis, 48% of patients with available cartilage data demonstrated advanced degeneration (grade ≥ 3). No statistically significant differences in recurrence risk were observed between treatment strategies; arthroscopic synovectomy, open synovectomy, and total hip arthroplasty. However, comparisons were limited by heterogeneous patient selection and follow-up duration. Arthroplasty was associated with the highest complication rate (33%), primarily aseptic loosening (19%). In the institutional cohort, 21.7% experienced recurrence and 29.4% required conversion to THA. Recurrences and conversions occurred exclusively in D-TGCT. PROMIS-CAT pain interference scores remained elevated (mean T-score 63.4 ± 11.1). Conclusion: Hip TGCT shows substantial cartilage damage at diagnosis and persistent postoperative morbidity. While recurrence rates appear comparable between surgical strategies, arthroplasty carries a higher complication burden in this predominantly young population. Prospective multicenter studies with standardized outcome reporting are required to optimize treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.